UCB dedicates its Georgia site for a $2 billion biologics campus due in 2032 or 2033

Set the $2 billion ^[1] against 330 permanent jobs ^[5] and the result is roughly $6.1 million of capital per job ^[16]. The campus is meant to apply artificial intelligence, automation and advanced manufacturing technologies ^[4], so a high ratio is unsurprising. The figure cannot separate equipment from buildings and land. The more than 1,000 construction jobs ^[8] are tied to the six- to seven-year build ^[7] and do not enter the ratio.

The public share is easier to size and harder to interpret. Gwinnett County's $174 million ^[6] comes to about $527,000 per permanent job ^[17]. GEN's report describes the sum as incentives and infrastructure investments together, so the split between money that reaches UCB and money spent on roads or utilities is not visible.

UCB's chief executive framed the project as a commitment to patients. "Our manufacturing investment in the United States reflects our long-term commitment to patients, strengthening our ability to serve them while contributing to scientific innovation, highly skilled jobs, and economic growth in Georgia," Jean-Christophe Tellier said in a statement ^[10]. UCB also listed Georgia's life sciences ecosystem, skilled workforce, infrastructure and access to academic and research institutions as reasons for the choice ^[11].

The thing this doesn't tell you is output. The report does not say how much the plant will make, which products it will make first, or whether any existing production moves from abroad. In our view that makes this a long-dated capacity bet by a company that already employs more than 2,000 people in the United States ^[13]. It will be judged in the early 2030s, on whether demand for the medicines it makes holds up.